Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kiniksa Pharmaceuticals Ltd.

28.04
-0.4500-1.58%
Volume:8.69M
Turnover:243.78M
Market Cap:2.05B
PE:-118.99
High:28.86
Open:28.50
Low:27.91
Close:28.49
Loading ...

Evercore ISI Remains a Buy on Kiniksa Pharmaceuticals (KNSA)

TIPRANKS
·
28 Feb

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
25 Feb

Kiniksa Pharmaceuticals Swings to Q4 Loss, Revenue Increases

MT Newswires Live
·
25 Feb

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Total Revenue $122.5M, vs. FactSet Est of $123.4M

MT Newswires Live
·
25 Feb

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Net Loss $-0.12 a Share, vs. FactSet Est of $-0.06 Loss

MT Newswires Live
·
25 Feb

Kiniksa Expects 2025 Arcalyst Net Product Revenue Of Between $560M-$580M

Benzinga
·
25 Feb

Kiniksa Pharmaceuticals Q4 2024 GAAP EPS $(0.12) May Not Be Comparable To $0.04 Estimate, Sales $122.54M Miss $123.38M Estimate

Benzinga
·
25 Feb

Kiniksa : Has Exercised Its Right to Terminate Its Exclusive License Agreement for Mavrilimumab With Medimmune

THOMSON REUTERS
·
25 Feb

Kiniksa Pharmaceuticals International Plc: to Discontinue Abiprubart Development in SjÖGren's Disease

THOMSON REUTERS
·
25 Feb

Kiniksa Pharmaceuticals International Plc - Arcalyst 2025 Net Product Revenue Expected $560-$580 Million

THOMSON REUTERS
·
25 Feb

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

GlobeNewswire
·
25 Feb

Evercore ISI Reaffirms Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)

TIPRANKS
·
04 Feb

Exploring High Growth Tech Stocks in the United States

Simply Wall St.
·
29 Jan

Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?

Zacks
·
14 Jan

Kiniksa Pharmaceuticals Reports Preliminary Q4 And FY2024 Arcalyst Net Product Revenue Of $121.9M And $416.4M, Respectively

Benzinga
·
13 Jan

Kiniksa Pharmaceuticals International - Arcalyst 2025 Net Product Revenue Expected $560-$580 Million

THOMSON REUTERS
·
13 Jan

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

GlobeNewswire
·
13 Jan

Kiniksa Pharmaceuticals (KNSA) Gets a Buy from Jefferies

TIPRANKS
·
05 Jan